This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lefranc, F. Articles by Kiss, R. Search for Related Content PubMed PubMed Citation Articles by Lefranc, F. Articles by Kiss, R.

Possible Future Issues in the Treatment of Glioblastomas: Special Emphasis on Cell Migration and the Resistance of Migrating Glioblastoma Cells to Apoptosis

From the Department of Neurosurgery, Erasmus University Hospital; and Laboratory of Toxicology, Institute of Pharmacy, Free University of Brussels, Brussels, Belgium

Address reprint requests to Robert Kiss, PhD, Laboratoire de Toxicologie, Institut de Pharmacie, Université Libre de Bruxelles, Campus de la Plaine, Blvd du Triomphe, 1050 Brussels, Belgium; e-mail: rkiss{at}ulb.ac.be

PURPOSE: The present review aims to emphasize that malignant gliomas are characterized by the diffuse invasion of distant brain tissue by a myriad of single migrating cells that exhibit decreased levels of apoptosis (programmed cell death type I), thus a resistance to cytotoxic insult.

METHODS: The present review surveys the molecular mechanisms of migration in malignant gliomas and potential issues arising from treatments, in addition to relationships between glioma cell migration and resistance to apoptosis in terms of the molecular signaling pathways.

RESULTS: Clinical and experimental data demonstrate that glioma cell migration is a complex combination of multiple molecular processes, including the alteration of tumor cell adhesion to a modified extracellular matrix, the secretion of proteases by the cells, and modifications to the actin cytoskeleton. Intracellular signaling pathways involved in the acquisition of resistance to apoptosis by migrating glioma cells concern PI3K, Akt, mTOR, NF-B, and autophagy (programmed cell death type II).

CONCLUSION: A number of signaling pathways can be constitutively activated in migrating glioma cells, thus rendering these cells resistant to cytotoxic insults. However, these pathways are not all constitutively activated at the same time in any one glioma. Particular inhibitors should therefore only be chosen if the target is present in the tumor tissue, but this is only possible if individual patients are submitted to the molecular profiling of their tumors before undergoing any treatment to combat their migratory glioma cells. Specific antimigratory compounds should be added to conventional radio- and/or chemotherapy.

R.K. is a Director of Research with the Fonds National de la Recherche Scientifique (FNRS, Belgium).

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				J. H. Overmeyer, A. Kaul, E. E. Johnson, and W. A. Maltese Active Ras Triggers Death in Glioblastoma Cells through Hyperstimulation of Macropinocytosis Mol. Cancer Res., June 1, 2008; 6(6): 965 - 977. [Abstract] [Full Text] [PDF]

				R. Liu, B. Tian, M. Gearing, S. Hunter, K. Ye, and Z. Mao Cdk5-mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasion PNAS, May 27, 2008; 105(21): 7570 - 7575. [Abstract] [Full Text] [PDF]

				F. Lefranc, V. Facchini, and R. Kiss Proautophagic Drugs: A Novel Means to Combat Apoptosis-Resistant Cancers, with a Special Emphasis on Glioblastomas Oncologist, December 1, 2007; 12(12): 1395 - 1403. [Abstract] [Full Text] [PDF]

				F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M. Stommel, A. Stegh, W. C. Hahn, K. L. Ligon, D. N. Louis, C. Brennan, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment Genes & Dev., November 1, 2007; 21(21): 2683 - 2710. [Abstract] [Full Text] [PDF]

				M. E. Wohlfahrt, B. C. Beard, A. Lieber, and H.-P. Kiem A Capsid-Modified, Conditionally Replicating Oncolytic Adenovirus Vector Expressing TRAIL Leads to Enhanced Cancer Cell Killing in Human Glioblastoma Models Cancer Res., September 15, 2007; 67(18): 8783 - 8790. [Abstract] [Full Text] [PDF]

				S. Ishiuchi, Y. Yoshida, K. Sugawara, M. Aihara, T. Ohtani, T. Watanabe, N. Saito, K. Tsuzuki, H. Okado, A. Miwa, et al. Ca2+-Permeable AMPA Receptors Regulate Growth of Human Glioblastoma via Akt Activation J. Neurosci., July 25, 2007; 27(30): 7987 - 8001. [Abstract] [Full Text] [PDF]

				E. H. Kim, S. Sohn, H. J. Kwon, S. U. Kim, M.-J. Kim, S.-J. Lee, and K. S. Choi Sodium Selenite Induces Superoxide-Mediated Mitochondrial Damage and Subsequent Autophagic Cell Death in Malignant Glioma Cells Cancer Res., July 1, 2007; 67(13): 6314 - 6324. [Abstract] [Full Text] [PDF]

				I. Camby, M. Le Mercier, F. Lefranc, and R. Kiss Galectin-1: a small protein with major functions Glycobiology, November 1, 2006; 16(11): 137R - 157R. [Abstract] [Full Text] [PDF]

				T. Rosenzweig, A. Ziv-Av, C. Xiang, W. Lu, S. Cazacu, D. Taler, C. G. Miller, R. Reich, Y. Shoshan, Y. Anikster, et al. Related to Testes-Specific, Vespid, and Pathogenesis Protein-1 (RTVP-1) Is Overexpressed in Gliomas and Regulates the Growth, Survival, and Invasion of Glioma Cells. Cancer Res., April 15, 2006; 66(8): 4139 - 4148. [Abstract] [Full Text] [PDF]

				P. Vajkoczy, P. Knyazev, A. Kunkel, H.-H. Capelle, S. Behrndt, H. von Tengg-Kobligk, F. Kiessling, U. Eichelsbacher, M. Essig, T.-A. Read, et al. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival PNAS, April 11, 2006; 103(15): 5799 - 5804. [Abstract] [Full Text] [PDF]